While for many systemic cancers, targeted treatments became part of the standard of care, in grade IV IDHwildtype gliomas (GBM), the clinical benefit is only seen in 1–2% of patients with v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations treated with BRAF p.V600E inhibitors5,6. The gene discussed is BRAF; the disease is central nervous system cancer.